Abilify Oral Solution

Abilify Oral Solution

aripiprazole

Manufacturer:

Otsuka
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Contents
Aripiprazole.
Indications/Uses
Irritability associated with autistic disorder.
Dosage/Direction for Use
Pediatric Patients 6-17 years: 5-15 mg daily. The dosage of Abilify Oral Solution should be individualized according to tolerability and response. Dosing should be initialized at 2 mg daily. The dose should be increased to 5 mg daily with subsequent increases to 10 or 15 mg daily, if needed. Dose adjustments of up to 5 mg daily should occur gradually at intervals of no less than 1 week.
Overdosage
Treatment should be symptomatic and supportive eg, adequate airway maintenance, cardiovascular monitoring and close medical supervision. Activated charcoal reduces serum concentration.
Contraindications
Hypersensitivity to aripiprazole.
Special Precautions
Clinical improvement may take several days to some weeks. Monitoring of the patient throughout this period is recommended. Reduce dose or discontinue if signs or symptoms of tardive dyskinesia appear. Discontinue if patient develops signs and symptoms indicative of neuroleptic malignant syndrome. Caution in patients with a history of seizure.
Effects on the Ability to Drive or Operate Machinery: Until individual patient response is established, caution is advised when driving or operating machines.
Use in pregnancy & lactation: Do not use in pregnancy unless the benefit outweighs the risk.
Breastfeeding is not advised during treatment.
Use In Pregnancy & Lactation
Do not use in pregnancy unless the benefit outweighs the risk.
Breastfeeding is not advised during treatment.
Adverse Reactions
Adverse events occurred in ≥10% of patients treated with Abilify Oral Solution are headache, nausea, vomiting, constipation, anxiety, insomnia, lightheadedness, somnolence, akathisia, dyspepsia, agitation.
Drug Interactions
Both CYP3A4 and CYP2D6 are responsible for Abilify Oral Solution metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in Abilify Oral Solution clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine or paroxetine) can inhibit Abilify Oral Solution elimination and cause increased blood levels.
MIMS Class
Antipsychotics
ATC Classification
N05AX12 - aripiprazole ; Belongs to the class of other antipsychotics.
Presentation/Packing
Oral soln 1 mg/mL x 150 mL x 1's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in